NCT07272772

Colon Cancer Diagnosis With FAPI-PET Imaging

Diagnostic Efficacy of 18F-FAPI-74 PET/CT in Patients With Colon Cancer

• Status: Recruiting
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Turku University Hospital · Other Government
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

Whole body CT is the primary imaging method in staging and follow-up of colon cancer. Conventional PET-CT with 18F-labeled fluorodeoxyglucose (18F-FDG) has its limitations and has a secondary role in colon cancer protocols. A new PET tracer, fibroblast activation protein inhibitor (FAPI), targeting a protein that is overexpressed by cancer-associated fibroblasts presents a potential new PET imaging tool. The objective of this prospective study is to evaluate diagnostic efficacy of 18F-FAPI-74 PET/CT in patients with colon cancer. The aim is to evaluate the sensitivity and specificity of 18F-FAPI-74 in detection of local lymph node metastasis and distant metastasis in patient level in patients with colon cancer in primary staging and when suspected recurrence. 100 patients with colon cancer are enrolled and PET/CT studies are performed with the novel 18F-FAPI-74 tracer. The data will be collected between 2024-2026.

Conditions

• Colon Cancer

Interventions

Type	Name	Description
DEVICE	PET/CT ([F-18]FAPI-74)	PET/CT with FAPI-74 tracer is performed

Timeline

• Start date: 2024-10-09
• Primary completion: 2026-10-01
• Completion: 2026-10-01
• First posted: 2025-12-09
• Last updated: 2025-12-09

Locations

1 site across 1 country: Finland